Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?
暂无分享,去创建一个
Luigi Bubacco | Mariano Beltramini | L. Bubacco | M. Beltramini | Marco Bisaglia | M. Bisaglia | Roberta Filograna | R. Filograna
[1] W. Bodell,et al. Detection of dopamine--DNA adducts: potential role in Parkinson's disease. , 1993, Carcinogenesis.
[2] V. Vasiliou,et al. Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase , 2007, Pharmacological Reviews.
[3] E. Hirsch,et al. Neuroinflammatory processes in Parkinson's disease. , 2005, Parkinsonism & related disorders.
[4] L. Chin,et al. Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. , 2010, Human molecular genetics.
[5] Minoru Harada,et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.
[6] L. Bubacco,et al. Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine , 2007, Journal of Biological Chemistry.
[7] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[8] D. Selkoe,et al. Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.
[9] D. Rubinsztein,et al. The roles of intracellular protein-degradation pathways in neurodegeneration , 2006, Nature.
[10] T. Nagatsu,et al. Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.
[11] M. Citron,et al. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.
[12] D. Leibfritz,et al. Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.
[13] L. Bubacco,et al. Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. , 2010, Biochimica et biophysica acta.
[14] Guohua Yu,et al. Quinoprotein Adducts Accumulate in the Substantia Nigra of Aged Rats and Correlate with Dopamine-Induced Toxicity in SH-SY5Y Cells , 2011, Neurochemical Research.
[15] D. Goldstein,et al. Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease , 2012, PloS one.
[16] D. Tucker,et al. Morphological development of the rat heart growing in oculo in the absence of hemodynamic work load. , 1990, Circulation research.
[17] A. Singleton,et al. alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.
[18] D. Standaert,et al. Targeted Overexpression of Human &agr;-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease , 2008, Journal of neuropathology and experimental neurology.
[19] M. Gutman,et al. Action of sulfhydryl inhibitors on different forms of the respiratory chain-linked reduced nicotinamide-adenine dinucleotide dehydrogenase. , 1970, Biochemistry.
[20] Melinda E. Lull,et al. Microglial activation and chronic neurodegeneration , 2010, Neurotherapeutics.
[21] D. Tse,et al. Potential oxidative pathways of brain catecholamines. , 1976, Journal of medicinal chemistry.
[22] A. Carlsson,et al. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species , 1986, Neuropharmacology.
[23] J. Doorn,et al. Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. , 2011, Chemico-biological interactions.
[24] S. Hunot,et al. Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.
[25] Graeme Eisenhofer,et al. Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine , 2004, Pharmacological Reviews.
[26] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[27] D. Sulzer,et al. Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.
[28] M. Sturlese,et al. Dopamine-derived Quinones Affect the Structure of the Redox Sensor DJ-1 through Modifications at Cys-106 and Cys-53* , 2012, The Journal of Biological Chemistry.
[29] T. Nagatsu,et al. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. , 1996, Neuroscience letters.
[30] D. Sulzer,et al. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics , 2003, Trends in Neurosciences.
[31] Peter T Lansbury,et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. , 2008, The Journal of clinical investigation.
[32] S. Iversen,et al. Dopamine: 50 years in perspective , 2007, Trends in Neurosciences.
[33] Diana Brahams,et al. Medicine and the Law , 1983, The Lancet.
[34] C. Shults. Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. Cookson. Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. , 2012, Cold Spring Harbor perspectives in medicine.
[36] M. Cascio,et al. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: Implications for Parkinson disease , 2008, Neurobiology of Disease.
[37] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] Keith D Wilkinson,et al. Familial Parkinson's Disease-associated L166P Mutation Disrupts DJ-1 Protein Folding and Function* , 2004, Journal of Biological Chemistry.
[39] M. Zigmond,et al. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[40] A. Lees,et al. Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.
[41] C. A. D. Costa,et al. DJ-1: a newcomer in Parkinson's disease pathology. , 2007, Current molecular medicine.
[42] Leonidas Stefanis,et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.
[43] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[44] G. Cohen,et al. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[45] Xin Zhao,et al. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Cookson,et al. Mitochondria and Dopamine New Insights into Recessive Parkinsonism , 2004, Neuron.
[47] Philippe Amouyel,et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.
[48] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[49] R. Mohney,et al. Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.
[50] Patrizia Rizzu,et al. Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.
[51] S. Berman,et al. Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria , 1999, Journal of neurochemistry.
[52] Roberto Cappai,et al. Modulation of α-Synuclein Aggregation by Dopamine: A Review , 2009, Neurochemical Research.
[53] T. Lim,et al. Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones , 2009, Free radical research.
[54] L. Greene,et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[55] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[56] D. Goldstein,et al. Catechols in post‐mortem brain of patients with Parkinson disease , 2011, European journal of neurology.
[57] Michael Cascio,et al. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells , 2009, Neurobiology of Disease.
[58] M. Beal. Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[59] H. Ischiropoulos,et al. Cellular Oligomerization of α-Synuclein Is Determined by the Interaction of Oxidized Catechols with a C-terminal Sequence* , 2007, Journal of Biological Chemistry.
[60] L. Bubacco,et al. Dopamine quinones interact with alpha-synuclein to form unstructured adducts. , 2010, Biochemical and biophysical research communications.
[61] Jun Hu,et al. Inhibition of α‐synuclein fibrillization by dopamine analogs via reaction with the amino groups of α‐synuclein , 2005 .
[62] A. Reichert,et al. Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin , 2007, The Journal of Neuroscience.
[63] A. Whitworth,et al. Molecular Mechanisms of PINK1-Related Neurodegeneration , 2011, Current Neurology and Neuroscience Reports.
[64] S. Jana,et al. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. , 2005, Biochimica et biophysica acta.
[65] Jie Li,et al. Dopamine and L‐dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[66] H. Büeler. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson’s disease , 2010, Apoptosis.
[67] G. Cohen,et al. Monoamine Oxidase and Mitochondrial Respiration , 1999, Journal of neurochemistry.
[68] D. Ross,et al. A Potential Role for Cyclized Quinones Derived from Dopamine, DOPA, and 3,4-Dihydroxyphenylacetic Acid in Proteasomal Inhibition , 2006, Molecular Pharmacology.
[69] Wenjie Xie,et al. Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease , 2001, The Journal of Neuroscience.
[70] C. Perier,et al. Neurotoxin-based models of Parkinson's disease , 2012, Neuroscience.
[71] P. Riederer,et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. , 1994, Neuroscience letters.
[72] C. Masters,et al. The structure of dopamine induced α-synuclein oligomers , 2010, European Biophysics Journal.
[73] W. Streit. Microglia as neuroprotective, immunocompetent cells of the CNS , 2002, Glia.
[74] M. Zigmond,et al. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. , 1997, Journal of neural transmission. Supplementum.
[75] A. Lees,et al. A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.
[76] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[77] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[78] Jun Hu,et al. Inhibition of α‐synuclein fibrillization by dopamine analogs via reaction with the amino groups of α‐synuclein , 2005 .
[79] R. Youle,et al. Parkin-induced mitophagy in the pathogenesis of Parkinson disease , 2009, Autophagy.
[80] F. Lee,et al. Genetic factors involved in the pathogenesis of Parkinson's disease , 2008, Brain Research Reviews.
[81] S. Bottomley,et al. Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[82] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[83] L. Bubacco,et al. Human SOD2 Modification by Dopamine Quinones Affects Enzymatic Activity by Promoting Its Aggregation: Possible Implications for Parkinson’s Disease , 2012, PloS one.
[84] C. Ross,et al. What is the role of protein aggregation in neurodegeneration? , 2005, Nature Reviews Molecular Cell Biology.
[85] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[86] K. Vrana,et al. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase , 1998, Journal of neuroscience research.
[87] E. Cavalieri,et al. Formation of dopamine quinone‐DNA adducts and their potential role in the etiology of Parkinson's disease , 2011, IUBMB life.
[88] D. Kuhn,et al. Dopamine Quinones Activate Microglia and Induce a Neurotoxic Gene Expression Profile , 2006, Annals of the New York Academy of Sciences.
[89] E. Floor,et al. Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.
[90] Cristine Alves da Costa. DJ-1: a newcomer in Parkinson's disease pathology. , 2007, Current molecular medicine.
[91] J. Doorn,et al. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. , 2009, Chemical research in toxicology.
[92] R. Fariello,et al. A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease , 2006, Neurology.
[93] E. Jayatilleke,et al. Inhibition of brain mitochondrial respiration by dopamine: involvement of H2O2 and hydroxyl radicals but not glutathione–protein–mixed disulfides , 2002, Journal of neurochemistry.
[94] Belinda Wilson,et al. Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[95] E. Masliah,et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.
[96] M. Bulsara,et al. Association of domestic exposure to volatile organic compounds with asthma in young children , 2004, Thorax.
[97] M. LaVoie,et al. Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.
[98] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[99] F. Helmchen,et al. Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.
[100] G. Zeevalk,et al. Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine‐associated diseases , 2004, Journal of neurochemistry.
[101] L. Elferink,et al. Tyrosine Hydroxylase Is Inactivated by Catechol‐Quinones and Converted to a Redox‐Cycling Quinoprotein , 1999, Journal of neurochemistry.
[102] K. Jellinger,et al. Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.
[103] A. Bentivoglio,et al. PINK1 mutations are associated with sporadic early‐onset parkinsonism , 2004, Annals of neurology.
[104] A. Abeliovich,et al. DJ-1 Is a Redox-Dependent Molecular Chaperone That Inhibits α-Synuclein Aggregate Formation , 2004, PLoS biology.
[105] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[106] S. Ambrosio,et al. The decrease of NAD(P)H has a prominent role in dopamine toxicity. , 2006, Biochimica et biophysica acta.
[107] A. Schapira,et al. Oxidative stress in Parkinson's disease , 1995, Neuropathology and applied neurobiology.
[108] J. Trojanowski,et al. Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations* , 2005, Journal of Biological Chemistry.
[109] Michael P. Murphy,et al. How mitochondria produce reactive oxygen species , 2008, The Biochemical journal.
[110] C. Marsden,et al. Oxidative Stress and Parkinson's Disease a , 1996, Annals of the New York Academy of Sciences.
[111] David N Hauser,et al. Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. , 2013, Free radical biology & medicine.
[112] L. Sanders,et al. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. , 2013, Free radical biology & medicine.
[113] P. Lansbury,et al. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.
[114] Steven P Gygi,et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. , 2005, Human molecular genetics.
[115] S. Greenfield,et al. Autoxidation of dopamine: a comparison of luminescent and spectrophotometric detection in basic solutions. , 1995, Free radical biology & medicine.
[116] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[117] T. Montine,et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.